IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,82 -0,85 (-1,02%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
58.797,46 +501,61 (+0,86%)
BioLife Solutions, Inc. (BLFS)
Después del cierre:
BioLife Solutions, Inc.
3303 Monte Villa Parkway
Suite 310
Bothell, WA 98021
United States
425 402 1400
https://www.biolifesolutions.com
Sector(es): Healthcare
Sector: Medical Instruments & Supplies
Empleados a tiempo completo: 409
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Roderick de Greef | CEO & Chairman | 1,63M | N/A | 1960 |
| Mr. Troy Wichterman | Chief Financial Officer | 485,2k | 17,47k | 1985 |
| Ms. Karen Foster | Chief Quality & Operations Officer | 395,2k | N/A | 1960 |
| Dr. Aby J. Mathew Ph.D. | Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer | 448,2k | 2,68M | 1972 |
| Mr. Todd Berard | Chief Marketing Officer | 286,49k | N/A | 1969 |
| Ms. Sarah Aebersold J.D. | Chief Human Resources Officer | N/A | N/A | 1977 |
| Mr. Garrie Richardson B.Sc., M.B.A. | Chief Revenue Officer | N/A | N/A | 1973 |
Descripción
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Gobierno corporativo
El ISS Governance QualityScore de BioLife Solutions, Inc., a día 1 de mayo de 2024, es 6. Las puntuaciones base son Auditoría: 10; Tablero: 8; Derechos de los accionistas: 3; Compensación: 6.
